Related Experiment Video
Updated: Feb 11, 2026
DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer
Indira Tirado-Hurtado1, Williams Fajardo2, Joseph A Pinto1
1Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru.
Abstract:
DNA damage inducible transcript 4 (DDIT4) gene is expressed under stress situations turning off the metabolic activity triggered by the mammalian target of rapamycin (mTOR). Several in vitro and in vivo works have demonstrated the ability of DDIT4 to generate resistance to cancer therapy. The link between the metabolism suppression and aggressiveness features of cancer cells remains poorly understood since anti-mTOR agents who are part of the repertoire of drugs used for systemic treatment of cancer achieving variable results. Interestingly, the high DDIT4 expression is associated with worse outcomes compared to tumors with low DDIT4 expression, seen in a wide variety of solid and hematological tumors, which suggests the driver role of this gene and provide the basis to target it as part of a new therapeutic strategy. In this review, we highlight our current knowledge about the biology of DDIT4 and its role as a prognostic biomarker, encompassing the motives for the development of target drugs against DDIT4 as a better target than mTOR inhibitors.
Insights
The DNA damage inducible transcript 4 (DDIT4) gene promotes cancer therapy resistance by suppressing metabolism. Targeting DDIT4 offers a promising therapeutic strategy, potentially outperforming mTOR inhibitors for better cancer treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- The DNA damage inducible transcript 4 (DDIT4) gene is activated under stress, inhibiting mammalian target of rapamycin (mTOR)-mediated metabolic activity.
- DDIT4 expression is linked to cancer therapy resistance and poorer patient outcomes across various tumor types.
- The precise mechanisms connecting metabolic suppression by DDIT4 to cancer cell aggressiveness are not fully understood.
Purpose of the Study:
- To review the current understanding of DDIT4 gene biology.
- To explore DDIT4's role as a prognostic biomarker in cancer.
- To provide rationale for developing DDIT4-targeted therapies as an alternative to mTOR inhibitors.
Main Methods:
- Literature review of in vitro and in vivo studies on DDIT4.
- Analysis of clinical data correlating DDIT4 expression with patient outcomes.
- Comparative analysis of DDIT4 targeting versus mTOR inhibition.
Main Results:
- High DDIT4 expression is associated with increased resistance to cancer therapy.
- Elevated DDIT4 levels correlate with worse prognosis in both solid and hematological malignancies.
- DDIT4's role suggests it as a potential driver of tumor aggressiveness.
Conclusions:
- DDIT4 plays a significant role in cancer progression and therapy resistance.
- DDIT4 serves as a valuable prognostic biomarker.
- Targeting DDIT4 directly represents a potentially superior therapeutic strategy compared to inhibiting mTOR.
Related Concept Videos
02:42Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
02:16Transcription Factors
01:10Transcription
Transcription is the process of synthesizing RNA from a DNA sequence by RNA polymerase. It is the first step in producing a protein from a gene sequence. Additionally, many other proteins and regulatory sequences are involved in the proper synthesis of messenger RNA (mRNA). Regulation of transcription is responsible for the differentiation of all the different types of cells and often for the proper cellular response to environmental signals.
Transcription Can Produce Different Kinds...
01:58Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
02:36DNA Damage Can Stall the Cell Cycle
02:36DNA Damage can Stall the Cell Cycle